Cancer immunotherapy research has been studied for decades, according to Walter Urba, M.D., Ph.D., director of cancer research at the Robert W. Franz Cancer Research Center. “The first line of defense against cancer in the body is the immune system,” said Dr. Urba. "OX40 agonists have shown very intriguing preclinical and clinical behavior in specific activation of T cells to attack tumors, and I am pleased to have MedImmune engaged in moving OX40 forward into additional human studies."
Providence Cancer Center joins global collaboration, taking cancer treatment research to a new level. More »
Cancer researchers study a unique approach, combining radiation and immunotherapy treatments. More »
Telestroke puts stroke experts “in the room” 24/7. More »
Enter your ZIP to see local news and info
Providence Portland Medical Center will be upgrading two surface parking lots during May 29-July 31, 2013. Learn More »